|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||1.90|
|PE Ratio (TTM)||38.80|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MONCTON, NB , Jan. 16, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis has partnered with Canada's Smartest Kitchen (CSK), a leader in food product development, to expand the Company's ongoing research and development related to edible cannabis products. Following the legalization of adult use recreational cannabis in Canada in 2018, cannabis edibles are expected to be legalized later in 2019 with the draft amendments to The Cannabis Act for edibles having been issued by the Federal Government for public consultation on December 20, 2018 .
MONCTON, NB , Jan. 15, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis is pleased to announce it is the first in the Canadian cannabis industry to introduce Integra Boost packaging technology into its entire line of dry flower products from 1g to 15g to help maintain freshness, extend shelf life and enhance the overall customer experience.
Cannabis Stocks: CGC, TLRY, CRON, and Others Last Week ## Major cannabis stocks For the week ending January 11, most of the major cannabis stocks ended in the positive territory. The Horizons Marijuana Life Sciences ETF (HMMJ) gained nearly 17.5% between the closing on January 4 and the closing on January 11. ## Gainers Tilray (TLRY) emerged as the biggest gainer last week. Tilray rose nearly 37% after a private equity company stated that it will keep its investments in the company through the second half of 2019. Canopy Growth (WEED) (CGC) rose 36% last week. Canopy Growth got a boost after Constellation Brands provided some visibility on its earnings within the next 18 months. Canopy Growth received coverage initiation from two major investment firms. Aurora Cannabis (ACB) gained nearly 21% last week, while Cronos Group (CRON) rose 16% between the weeks ending January 4 and January 11. Aphria (APHA), which reported its earnings last week, rose 13.8%. Supreme Cannabis (SPRWF) gained nearly 12.7%, while CannTrust (CNTTF) gained nearly 13.8%. OrganiGram (OGRMF) was also among the top gainers last week with a 10% gain. Emerald Health (EMHTF) was the only stock in the above chart that ended in the negative territory with a weekly decline of 1.3%. To learn more about the cannabis sector, read Why Green Growth Stock Rose Yesterday, Jim Cramer Made His Pick in the Cannabis Industry, and Canopy Growth: Notes from Constellation Brands’ Earnings.
CORAL GABLES, FL / ACCESSWIRE / January 11,2019 / The marijuana industry has been anything but safe over the course of the past year to two years, during the course of which top players in the industry saw huge boosts in investor interest. ), OrganiGram Holdings Inc (OGRMF) (OGI.V), Namaste Technologies Inc (NXTTF), and GW Pharmaceuticals Plc (GWPH) are 4 pot stocks that could make moves on Friday. The Company has been referred to as the "Priceline of Pot" by several sources, and similarly to the site which provides travel deals, Leafbuyer is the most comprehensive online source for cannabis deals and specials.
CORAL GABLES, FL / ACCESSWIRE / January 10, 2019 / The way people receive health care, including how the medical field continues its integration of medical marijuana, is evolving. As public opinion surrounding cannabis becomes increasingly more favorable, marijuana stocks may begin to present an appealing opportunity for investors looking into the nascent sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), OrganiGram Holdings Inc (OGRMF), GW Pharmaceuticals Plc (GWPH), and Aphria Inc (APHA) represent 4 pot stocks that are heating up on Thursday.
CannTrust Holdings: Analysts Are Mainly Positive in January (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, CannTrust Holdings’ (CNTTF) net revenues grew ~115% YoY (year-over-year) to 29.5 million Canadian dollars from 13.7 million Canadian dollars. In the third quarter, CannTrust Holdings generated net revenues of 12.6 million Canadian dollars compared to 6.1 million Canadian dollars in the same period the previous year, which reflected ~105% YoY growth. Analysts expect CannTrust Holdings to generate net revenues of 28.29 million in the fourth quarter. Analysts expect the company’s net revenues for fiscal 2018 to be ~60.64 million Canadian dollars. CannTrust Holdings’ peers in the licensed cannabis market, OrganiGram (OGRMF) and HEXO (HYYDF) generated net revenues of 12.43 million Canadian dollars and 4.9 million Canadian dollars, respectively, in fiscal 2018, which reflects ~60.54% and ~20.43% YoY growth. HEXO reported net revenues of 5.6 million Canadian dollars in the first quarter of 2019. ## Gross profit and EBITDA In the first nine months of 2018, CannTrust Holdings reported a gross profit and adjusted EBITDA of 44.8 million Canadian dollars and 1.2 million Canadian dollars, respectively—compared to 12.9 million Canadian dollars and 3.5 million Canadian dollars during the same period the previous year. In the third quarter, CannTrust Holdings’ gross profit and adjusted EBITDA were 12.5 million Canadian dollars and 557,983 Canadian dollars, respectively—compared to 5.4 million Canadian dollars and 1.9 million Canadian dollars during the same period the previous year. Continue to Next Part Browse this series on Market Realist: * Part 1 - CannTrust Holdings: Analysts Are Mainly Positive in January * Part 3 - CannTrust Holdings’ Earnings Trends and Recent Developments * Part 4 - Analyzing CannTrust Holdings’ Medical and Wholesale Business
CannTrust Holdings: Analysts Are Mainly Positive in January ## Stock performance On January 8, CannTrust Holdings’ (CNTTF) stock price closed at $5.63, which is ~3.04% growth from its close of $5.47 on January 7. On January 4, the company’s stock price grew ~4.18% to $5.36 from its close of $5.14 on January 3. On December 31, CannTrust Holdings’ stock price closed at $4.82 and reached $5.63 on January 8, which represents ~17% growth over the first five trading days of 2019. On January 8, CannTrust Holdings’ stock price closed at $5.63, which is ~29% growth from its 52-week low of $4.35 on December 24. The company hit its 52-week high of $11.97 on October 16. ## Listing on the NYSE On January 8, CannTrust Holding announced that it applied for its common shares to be listed on the NYSE. CannTrust Holdings will be listed on the NYSE after it satisfies all of the regulatory requirements and gets approval from the NYSE. According to the requirements, the company filed a Form 40-F registration statement with the SEC. ## Analysts’ recommendations Among the nine analysts tracking CannTrust Holdings in January, three recommended a “strong buy,” while six recommended a “buy.” In January, among the nine analysts tracking OrganiGram (OGRMF), three recommended a “strong buy,” while six recommended a “buy.” Among the ten analysts tracking HEXO (HYYDF), two recommended a “strong buy,” while eight recommended a “buy.” Continue to Next Part Browse this series on Market Realist: * Part 2 - CannTrust Holdings: Financial Overview in January * Part 3 - CannTrust Holdings’ Earnings Trends and Recent Developments * Part 4 - Analyzing CannTrust Holdings’ Medical and Wholesale Business
Leading the way, NASDAQ’s first listed cannabis stock, Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) and Ginkgo Bioworks, the organism company, in early September announced a partnership to produce cultured cannabinoids.
The Latest from Aphria: Green Growth, Irwin Simon, and More (Continued from Prior Part) ## Aphria’s value Investors often look at valuations to determine whether a stock is trading cheap or at a premium before making an investment decision. In its commitment to take over Aphria, Green Growth discussed what makes Aphria valuable. Green Growth indicated value in “Aphria’s veteran greenhouse industry and pharmaceutical operations” and its “Canadian supply and wholesale agreements.” One of the most important considerations about Green Growth’s assessment of value appears to indicate that on a standalone basis, Aphria’s production capacity and its supply agreements can create value for any partner that can bring retail experience and access to the US market with deep pockets. We’ve already seen that Constellation Brands and more recently, Altria, two big US players, have established partnerships with Canopy Growth and Cronos Group, respectively. The above chart shows cannabis industry valuations. We have discussed valuations in depth along with valuations for companies (HMMJ) including Aphria (APHA), Canopy Growth (WEED), Tilray (TLRY), Organigram (OGRMF), and others. Read Which Cannabis Stocks Look Cheap in December to learn more. Continue reading to learn about other updates on Aphria last week. Continue to Next Part Browse this series on Market Realist: * Part 1 - The Latest from Aphria: Green Growth, Irwin Simon, and More * Part 2 - Is Aphria Really a ‘Failed Investment’ as Green Growth Indicated * Part 4 - Did Green Growth Just Take a Swipe at Aphria’s Short Sellers?
Scotts Miracle-Gro: Suntrust Robinson Lowered Its Target Price ## Scotts Miracle-Gro’s price cut On January 4, Suntrust Robinson lowered its target price for Scotts Miracle-Gro (SMG) to $90 from $100. Scotts Miracle-Gro missed analysts’ estimates in three of the past four quarters. The stock declined almost 43% in 2018. While the company had been a promising bet for cannabis investors (MJ), the recent news weakened investors’ sentiment. ## Consensus The overall consensus recommendation for Scotts Miracle-Gro’s target price in the first week of 2019 was $84.5, which was lower than last month’s consensus target price of $92.3. The target price was $102 at the beginning of 2018. As of January 4, the stock closed at $64.5, which would mean an upside of ~31% to the target price. The overall recommendation from the seven analysts in the above chart was still a “buy.” One analyst recommended a “strong buy,” while three analysts recommended a “buy” on the stock for the next 12 months. Two analysts maintained a “hold” recommendation, while one analyst recommended a “sell” on the stock. While there were some losses in the mainstream cannabis sector, stocks like Canopy Growth (WEED) (CGC), Cronos Group (CRON), and OrganiGram (OGRMF) ended in the positive territory in 2018.
Aphria’s (APHA) sales are expected to increase ~350% in the second quarter of 2019. Analysts expect the sales to impact the company’s EBITDA margins as well.
In this series, we have discussed how the cannabis sector (MJ) looked cheap in December based on the forward EV-to-sales multiple. In this part, we’ll discuss the forward EV-to-EBITDA multiple.
In 2018, over 75 percent of securities that upgraded to OTCQX, the highest tier of OTC Markets, were in the cannabis, basic materials, and financial sectors. (According to an analysis of issuer data.) ...
OrganiGram (OGRMF) has remained in the positive territory YTD (year-to-date) with the stock returning ~2.4%. The Horizons Marijuana Life Sciences ETF (HMMJ) has a negative return of 29.5% YTD, while the ETFMG Alternative Harvest ETF (MJ) has a negative return of 27.3%.
The company wants to benefit from strong market growth trends in the future. According to Auxly Cannabis’ corporate presentation, the total demand for cannabis is expected to exceed the supply by 2021. To leverage the opportunity, Auxly Cannabis has been focused on expanding its cultivation capacity organically or inorganically through partnerships, commercial off-take arrangements, and joint ventures.
With 2018 almost coming to an end, it’s time to look at analysts’ ratings and target price for major cannabis stocks. As of December 18, Canopy Growth (WEED) has returned nearly 32% to investors. The stock has been one of the most favored stocks due to its vast portfolio of companies and products.
MONCTON, NB , Dec. 19, 2018 /CNW/ - Organigram Holdings Inc. (TSX VENTURE:OGI) (OGRMF) (the "Company" or "Organigram"), a leading licensed producer of cannabis based in Moncton, New Brunswick , announces the results of its 2018 Annual and Special Meeting of Shareholders (the "Meeting") adjourned from Friday December 7, 2018 and reconvened on Monday, December 17, 2018 in Toronto . Shareholders voted to elect all seven of management's nominees to the Board of Directors of the Company, being returning directors Peter Amirault , Derrick West , Michel Bourque , Dr. Kenneth Mitton and Greg Engel , as well as new management nominees Dexter John and Sherry Porter . All directors are "independent" as defined under securities laws, excepting Greg Engel who is also the Chief Executive Officer of the Company.
The cannabis industry will likely continue to move beyond early-stage products such as dried cannabis flower to more value-added products with a variety of uses and formats of consumption. Companies (HMMJ) such as Canopy Growth (WEED), Cronos Group (CRON), Organigram (OGRMF), and CannTrust (CNTTF) may move to differentiate their products including extracts, gels, oils, and other formats to carve out their niche in the highly competitive market. The next development that we’ll be closely watching in 2019 is consolidation and synergies. We’ll be interested in seeing how the cannabis market continues to consolidate with more acquisitions. We’ll also be watching the evolution of partnerships and ventures between cannabis companies with the goal of taking advantage of synergies.
Capacity expansion, brand building, and supply deals are now in focus, with sales growth expected to really pick up in fiscal 2019.
Results to August 31, 2018 showcase a Canadian leader in low-cost cultivation while growing high-quality indoor product MONCTON, NB , Dec. 14, 2018 /PRNewswire/ - Organigram Holdings Inc. (TSX VENTURE: ...